WeedMD Inc. Now Selling Cannabis Clones
Toronto, Canada, June 13, 2017 — WeedMD Inc. (TSX-V:WMD) (“WeedMD” or the “Company”), a federally licensed producer of medical cannabis, is pleased to announce that it will begin selling cannabis clones to patients registered for home grow under the Access to Cannabis for Medical Purposes Regulations.
“With the recent announcement launching sales of dried cannabis and now sales of cannabis plants, we look forward to serving medical patients with our high quality genetics,” said Bruce Dawson-Scully, CEO of WeedMD. “We are extremely supportive of home grow and are excited to offer access to our unique genetics to those that would prefer to grow their own medical cannabis. We undertook an intensive phenotyping process as we built inventory ahead of medical sales, and the strains we are offering reflect the results of our scientific research and development.”
Initially, WeedMD will offer several strains which have been chosen for their unique characteristics including cannabinoid profile, genetics, nutrient requirements, and ease of cultivation. The Company plans to provide additional strains in the future based on customer feedback.
Clones can be purchased on WeedMD’s website www.weedmd.com. The Company has structured its pricing to reflect its desire to provide patients with access to a variety of medical cannabis at a reasonable price.
About WeedMD Inc.
WeedMD Inc. is a licensed producer of medical cannabis pursuant to the Access to Cannabis for Medical Purposes Regulations (ACMPR). WeedMD operates a 26,000 square foot, scalable production facility in Aylmer, Ontario with over four acres of property for future expansion. WeedMD is focused on providing consistent, quality medicine to the long-term care and assisted living markets in Canada through its comprehensive platform developed exclusively for that industry. WeedMD is dedicated to educating healthcare practitioners and furthering public understanding of the role medical cannabis can play as a viable alternative to prescription medication in relieving a variety of chronic medical conditions and illnesses.
Follow WeedMD On:
For further information, please contact:
Keith Merker, Chief Financial Officer
Tel: 519-765-2440 Ext. 222
To learn more, visit us at www.weedmd.com
This press release contains forward-looking information based on current expectations. Statements about the date of trading of the Company’s common shares on the Exchange and final regulatory approvals, among others, are forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law.
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE